COVID-19 Update: We are currently shipping orders daily. However, due to transit disruptions in some geographies, deliveries may be delayed. To provide all customers with timely access to content, we are offering 50% off Science and Technology Print & eBook bundle options. Terms & conditions.
Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Treating Neurodegenerative Diseases as Metabolic Diseases - 1st Edition - ISBN: 9780128231210, 9780128231227

Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Treating Neurodegenerative Diseases as Metabolic Diseases, Volume 155

1st Edition

Serial Volume Editors: Grazyna Soderbom Russell Esterline Jan Oscarsson Mark Mattson
Hardcover ISBN: 9780128231210
eBook ISBN: 9780128231227
Imprint: Academic Press
Published Date: 25th August 2020
Page Count: 322
Sales tax will be calculated at check-out Price includes VAT/GST
Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

    1. Dysregulation of metabolic flexibility: The impact of mTOR on autophagy in neurodegenerative diseases
    2. Kenneth Maiese

    3. Antidiabetic drugs for Alzheimer´s and Parkinson´s diseases: Repurposing insulin, metformin and thiazolidinediones
    4. Susana Cardoso and Paula I. Moreira

    5. Evidence for pathophysiological commonalities between metabolic and neurodegenerative diseases
    6. Christian Hölscher

    7. Repurposing GLP1 agonists for neurodegenerative diseases
    8. Ioanna Markaki, Kristian Winther, Sergiu-Bogdan Catrina and Per Svenningsson

    9. A role for Sodium Glucose coTransporter 2 inhibitors (SGLT2i) in the treatment of Alzheimer's disease?
    10. Russell Esterline, Jan Oscarsson and Jeffrey Burns

    11. Ketotherapeutics for neurodegenerative diseases
    12. Nicholas G. Norwitz, Javier Gilbert Jaramillo, Kieran Clarke and Adrian Soto

    13. Enhancing mitophagy as a therapeutic approach for neurodegenerative diseases
    14. Yahyah Aman, Brent Ryan, Silje Bøen Torsetnes, Anne-Brita Knapskog, Leiv Otto Watne, William A. McEwan and Evandro Fei Fang

    15. Cellular senescence in aging and age-related disorders: Implications for neurodegenerative diseases
    16. Erin O. Wissler Gerdes, Yi Zhu, Bettina M. Weigand, Utkarsh Tripathi, Terence C. Burns, Tamar Tchkonia and James L. Kirkland

    17. Harnessing neurogenesis in the adult brain—A role in type-2-diabetes mellitus and Alzheimer’s disease
    18. Orly Lazarov, Richard D. Minshall and Marcelo G. Bonini

    19. Hormesis: A therapeutic strategic approach in the treatment of neurodegenerative disease

Edward J. Calabrese, Mark P. Mattson, Gaurav Dhawan, Rachna Kapoor, Vittorio Calabrese and James Giordano


Metabolic Drivers and Bioenergetic Components of Neurodegenerative Disease reviews how the different aspects of metabolic dysfunction and consequent pathology associated with neurodegenerative diseases, including Alzheimer’s and Parkinson’s, can be targeted by novel treatment approaches. Topics covered include Cellular Senescence in Aging and Age-Related Disorders: Implications for Neurodegenerative Diseases; Repurposing GLP1 agonists for Neurodegenerative Diseases; Ketotherapeutics for Neurodegenerative Diseases; Enhancing Mitophagy as a Therapeutic Approach for Neurodegenerative Diseases; Harnessing Neurogenesis in the Adult Brain – A Role in Type 2 Diabetes Mellitus and Alzheimer’s disease; and much more.

Key Features

  • Summarizes the impact of the metabolic hypothesis on underlying mechanisms of neurodegenerative diseases
  • Presents novel, potential treatment strategies based on the metabolic hypothesis for neurodegenerative diseases.


Postgraduates and researchers in the areas of Neurobiology, Neurodegeneration, Alzheimer’s, Parkinson’s, Metabolic Disorders, Bioenergetics, Repurposing of Metabolic Treatments, Novel Treatments for Neurodegenerative Disorders.


No. of pages:
© Academic Press 2020
25th August 2020
Academic Press
Hardcover ISBN:
eBook ISBN:

Ratings and Reviews

About the Serial Volume Editors

Grazyna Soderbom

Grazyna Soderbom

Grażyna Söderbom, PhD is founder of Klipspringer AB. She received her BSc 1st Class Hons in Pharmacology & Toxicology from King’s College, London and PhD in Neuroscience from the University of London. She spent one year of her undergraduate studies investigating the role of the AT2-receptor subtype at Ciba-Geigy under the tutelage of Dr Marc de Gasparo. As a Wellcome Trust PhD Scholar in Prof. Peter Jenner’s Neurodegenerative Research Group, Grażyna focused on the aetiology of Parkinson’s disease, specifically the relevance of antioxidant enzymes in the basal ganglia and Parkinson’s pathogenesis. After working as a Post-Doctoral Research Fellow at the Clinical Age Research Unit at King’s College Hospital, Grażyna joined Zeneca/AstraZeneca Pharmaceuticals, which included five years as Global Brand Manager in Cardiovascular Medicine in Sweden. She was involved in the global marketing and communications behind the antihypertensive Atacand® and the launch of Atacand Plus®. Having discovered a strong interest in strategic medical communications, Grażyna launched Klipspringer in 2013, which specializes in scientific, medical and strategic writing and consultation for Academia, Bio-Pharma and beyond. Grażyna is passionate about “all things science”, especially neuroscience, and the effective sharing of scientific knowledge to all levels of audiences. She has published scientific research of her own and now supports others in their scientific and medical communications. Grażyna is particularly interested in the potential implications of the link between metabolic disease and neurodegenerative disorders.

Affiliations and Expertise

Klipspringer, Sweden

Russell Esterline

Russell Esterline

Russell Esterline, PhD is currently a VP Global Medicines Leader at AstraZeneca Pharmaceuticals leading the advancement of late stage metabolic products towards registration and approval and beyond. He received his B.S. in Chemistry from Juniata College and his PhD in Toxicology from Rutgers University/UMDNJ Joint Graduate Program in Toxicology. He completed his Post-Doctoral training at the Johns Hopkins School of Hygiene and Public Health. Both pre- and post-graduate research focused on the impact of toxicants on mitochondrial function. At AstraZeneca, Russell led the development of CRESTOR (rosuvastatin) through its LCM delivery stage (METEOR, CORONA, AURORA, JUPITER, SATURN clinical trials) and more recently led the development of FARXIGA (dapagliflozin) through global approval and launch. As the FARXIGA lead, Russell became interested in understanding the underlying mechanism(s) behind the unique SGLT2i-driven benefit in patients with type 2 diabetes and has published a novel theory describing the metabolic underpinning of this benefit. If correct, this theory may have implications beyond the proven benefits on the heart and kidney into the CNS, a possibility which is currently being pursued through collaborations with leading scientists in the field.

Affiliations and Expertise

AstraZeneca, USA

Jan Oscarsson

Jan Oscarsson

Jan Oscarsson is MD, PhD in Physiology and Registered physician trained in internal medicine. He was appointed Professor in Physiology, especially Endocrinology and Integrative metabolism, in 2003 and was recruited by AstraZeneca R&D the same year. His academic work has focused on metabolic regulation in cell culture, animal and clinical studies. He has also been interested in the hormonal regulation of neurogenesis in collaboration with the late Professor Peter Eriksson. At AstraZeneca R&D, he has had several different positions in R&D, including Head of Section of Molecular Metabolism and Disease Area Portfolio Leader focusing on diabetes and metabolic regulation. Since 2013, he is Director Physician in Clinical Development, working on type 2 diabetes, dyslipidemia and fatty liver disease. During the last few years he has conducted studies to determine the mechanisms behind the unique SGLT2i-driven benefits in patients with type 2 diabetes, and together with Russ Esterline PhD, published a novel theory describing the metabolic underpinning of this benefit.

Affiliations and Expertise

AstraZeneca, Sweden

Mark Mattson

Mark Mattson

Dr. Mattson is a Professor of Neuroscience at Johns Hopkins University School of Medicine. After receiving his PhD degree from the University of Iowa, Dr. Mattson completed a postdoctoral fellowship in Developmental Neuroscience at Colorado State University. He then joined the Sanders-Brown Center on Aging at the University of Kentucky College of Medicine where he advanced to Full Professor. From 2000-2019 Dr. Mattson was the Chief of the Laboratory of Neurosciences at the National Institute on Aging in Baltimore where he brought neuroscience research to the forefront at that NIH Institute. Dr. Mattson’s research is aimed at understanding molecular and cellular mechanisms of brain aging and the pathogenesis of neurodegenerative disorders. His work has elucidated how the brain responds adaptively to challenges such as fasting and exercise, and he has used that information to develop novel interventions to promote optimal brain function throughout life. Dr. Mattson is among the most highly cited neuroscientists in the world with over 150,000 citations and an ‘h’ index of over 200. He was elected a Fellow of the American Association for the Advancement of Science, and has received many awards including the Metropolitan Life Foundation Medical Research Award, the Alzheimer’s Association Zenith Award and the Santiago Grisolia Chair Prize. He was the founding Editor and Editor-in-Chief of Ageing Research Reviews and Neuromolecular Medicine, and is currently a Reviewing or Associate Editor for the Journal of Neuroscience and Trends in Neurosciences.

Affiliations and Expertise

Johns Hopkins University School of Medicine, MD, USA